Health
Research trial benefits: Public health gains and lower health care costs
NEWS IN BRIEF — Posted May 15, 2006
A systematic evaluation of whether government investment in medical research yields gains in public health has found that new discoveries have been responsible for about 70,000 additional healthy years of life for the population.
The findings were reported in the April 22 issue of The Lancet.
The evaluation, sponsored by the National Institute of Neurological Disorders and Stroke, estimated the economic benefit to the United States from eight phase III trials exceeded $15 billion over the course of 10 years. Among the eight trials was one of tissue plasminogen activator for ischemic stroke that showed the tPA could prevent brain damage if used within the first three hours after a stroke begins.
The study is thought to be one of the first to analyze the impact of a publicly funded research program on medical care, public health and health care costs.
The investigators evaluated the costs and public health benefits of all 28 phase III trials that were conducted between 1977 and 2000. The total cost of funding the trials was $335 million. Information on the utilization of the tested therapies and their impact on societal costs and savings or quality of life was available for eight of the trials.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/05/15/hlbf0515.htm.












